Estamos no ar no ! Saiba mais
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Deslistada

MRTX foi retirado da bolsa em 22 de janeiro de 2024.

Voltar ao ranking
 

Sobre: Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

Funcionários: 593

Saúde Fabricantes de medicamentos — geral

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 0%
Neutro 0%
Negativo 0%
Positivo
Zacks Investment Research
há 2 anos
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
Neutro
PRNewsWire
há 2 anos
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previously received treatment with a platinum-based regimen and an immune checkpoint inhibitor.
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Positivo
CNBC
há 2 anos
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Positivo
Zacks Investment Research
há 2 anos
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
Ver ranking de notícias
Gráficos de preços implementados com Lightweight Charts™